FIMI Becomes Biggest Shareholder in Biomed Company Kamada
24.11.19|Golan Hazani and Tzally Greenberg
Nasdaq and Tel Aviv-listed Kamada develops protein-based pharmaceuticals for genetic disorders, as well as rabies antibodies and a serum against snake bites